Last edition
News about Global Pharma
Roche Boosts AI Muscle with Nvidia Chip Expansion to Accelerate Drug Discovery
Swiss pharma major Roche has significantly expanded its artificial intelligence (AI) capabilities by deploying thousands of advanced GPUs from Nvidia, marking one of the largest AI infrastructure investments in the pharmaceutical sector.
Global Pharma | 17/03/2026 | By Darshana | 115
Zuellig Pharma has acquired rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea, expanding its ownership of the men’s health drug across 11 Asian markets.
Global Pharma | 16/03/2026 | By News Bureau | 170
Epilepsy Foundation of America and youth-led nonprofit SeizeSense launch a national PSA campaign in US cinemas to educate audiences on seizure recognition and first aid.
Global Pharma | 10/03/2026 | By News Bureau | 104
Sanofi Board Nominates Christel Heydemann as Independent Director
Sanofi has nominated Christel Heydemann as an Independent Director, subject to shareholder approval at its AGM on 29 April. The company also announced that Patrick Kron, Independent Director and Chairman of the Nomination, Governance and CSR Committee, will step down at the end of his term.
Global Pharma | 07/03/2026 | By News Bureau | 168
UK Space Agency Launches Initiative to Accelerate Development of Space-Manufactured Medicines
UK Space Agency, with Medicines and Healthcare products Regulatory Agency and partners, unveils regulatory support and innovation programmes to help companies develop microgravity-manufactured medicines and bring them from orbit to patients.
Global Pharma | 07/03/2026 | By News Bureau | 107
IceCure Medical Study in PLOS One Highlights ProSense Cryoablation for Benign Breast Tumours
Independent Hungarian study shows ProSense cryoablation achieves up to 92.9 percent tumour reduction in fibroadenomas, supporting minimally invasive alternatives to surgery for benign breast lesions.
Global Pharma | 03/03/2026 | By News Bureau
IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC
Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.
Global Pharma | 02/03/2026 | By News Bureau | 107
China Approves Jaypirca for Relapsed CLL and SLL Patients
Jaypirca (pirtobrutinib) by Innovent Biologics has been approved in China for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The BTK inhibitor is designed to overcome resistance associated with prior covalent BTK therapies.
Global Pharma | 02/03/2026 | By News Bureau | 116
Japan's MHLW accepts GSK's Bepirovisen for Review to Treat Chronic Hepatitis B
Japan’s health ministry has accepted GSK’s new drug application for investigational antisense therapy bepirovirsen, after Phase III trials showed significantly higher functional cure rates in chronic hepatitis B patients.
Global Pharma | 27/02/2026 | By News Bureau | 471
India and Brazil Explore New Avenues to Strengthen Pharmaceutical Trade
India and Brazil are exploring new opportunities to expand bilateral pharmaceutical trade through enhanced regulatory cooperation and business engagement.
Global Pharma | 26/02/2026 | By Darshana | 159
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy